Clinical and pharmacological problems in implementation of clinical recommendations on the treatment of community acquired pneumonia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In routine clinical practice, a practicing physician follows clinical recommendations on the treatment of infectious diseases; but they, however, do not take into account a number of factors that have a significant influence on the choice of an antimicrobial drug under specific conditions. It is necessary to take into account regional and local features of the microbiological landscape, the presence of allergy, age and concomitant diseases, and, accordingly, the medications taken. Polypharmacy and drug-drug interactions can be the cause of iatrogeny, development of side effects and the loss of the expected clinical effectiveness of the therapy.

Full Text

Restricted Access

About the authors

D. V Tsyganko

City Clinical Hospital n.a. I.V. Davydovsky

N. G Berdnikova

City Clinical Hospital n.a. I.V. Davydovsky; I.M. Sechenov First Moscow State Medical University

PhD, Associate Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

L. M Krasnykh

Scientific Centre for Expert Evaluation of Medicinal Products

S. N Politkina

Scientific Centre for Expert Evaluation of Medicinal Products

O. Yu Klimova

I.M. Sechenov First Moscow State Medical University

Yu. A Antonovskiy

City Clinical Hospital n.a. I.V. Davydovsky

References

  1. Charles PG., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respirator or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-84.
  2. Чучалин А.Г. Синопальников А.И. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. 2010. URL: http://www.antibiotic.ru/cmac/ pdf/8_1_054.pdf
  3. Чучалин А.Г. Синопальников А.И. Козлов Р.С. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольнич-ной пневмонии. Пульмонология. 2014;4:13-48. doi: 10.18093/0869-0189-2014-0-4-13-482014. doi: 10.18093/0869-0189-2014-0-4-13-482014.
  4. Фесенко О.В., Синопальников А.И. Современные системы оценки внебольничной пневмонии тяжелого лечения: перспективы и ограничения. Клиническая микробиология и антимикробная терапия. 2011;3(13):204-13.
  5. Дворецкий Л.И. Пневмонии у сложных больных. Трудный пациент. 2010. URL: http://t-pacient.ru/ articles/6548/
  6. Muthu J., Muthanandam S., Mahendra J. Mouth the mirror of lungs: where does the connection lie? Front Med. 2016;10(4):405-9.
  7. Момот АП, Балацкая И.В., Мартыненко Т. И. и др. Показатели воспалительных реакций, гемостаза и эндотелиоза при тяжелой пневмонии в зависимости от исходов заболевания и их сопряжение. Современные проблемы науки и образования. 2014;2.
  8. Anderson R., Feldman C. Review manuscript: Mechanisms of platelet activation by the pneumococcus and the role of platelets in community-acquired pneumonia. J. Infect. 2017. pii: S0163-4453(17)30305-5. Doi: 10.1016/j. jinf.2017.09.013.
  9. Shenoy A.T., Brissac T., Gilley R.P. Streptococcus pneumoniae in the heart subvert the host response through biofilm-mediated resident macrophage killing. PLoS Pathog. 2017;13(8):e1006582.
  10. Kothe H., Bauer T., Marre R., et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008;32(1):139-46.
  11. Mullerova H., Chigbo C., Hagan G.W., et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124-33. Doi: 10.1016/j. rmed.2012.04.008.
  12. Torres A., Peetermans W.E., Viegi G., Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a lterature review. Thorax. 2013;68(11):1057-65. Doi: 10.1136/ thoraxjnl-2013-204282.
  13. Almirall J., Boll bar I., Serra-Prat M., et al. Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur. Respir. J. 2008;31(6):1274-84. doi: 10.1183/09031936.00095807.
  14. Lai S.W., Lin C.L., Liao K.F. Risk of pneumonia among patients with splenectomy: a retrospective population-based cohort study. Ann. Saudi Med. 2017;37(5):351-56.
  15. Yan L., Qing Y., Xingyi J., Hongbo Q. Etiologic diagnosis and clinical treatment of multiple drug-resistant bacteria infection in elderly patients with stroke-associated pneumonia after neurosurgery. Cell Biochem. Biophys. 2015;71(2):731-34.
  16. Shim R., Wong C. Ischemia, Immunosuppression and Infection - Tackling the Predicaments of Post-Stroke Complications. J. Mol Sci. 2016;17(1):64.
  17. Slinin Y, Foley R.N., Collins A.J. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70(6):1135-41.
  18. Программа СКАТ при оказании стационарной медицинской помощи. Методические рекомендации. 2016. URL: http://www.antimicrob.net/
  19. Овчинникова Е.А., Овчинникова Л.К. Основные механизмы развития неблагоприятных побочных реакций. Качественная клиническая практика. 2004;1:57-66.
  20. Рафальский В.В. Нежелательные лекарственные реакции и взаимодействия при антибиотикоте-рапии при инфекции мочевыводящих путей. Методическое пособие. URL: http://www.antibiotic. ru/rus/all/metod/nlr/
  21. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2): 512-21.
  22. Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin. Proc. 2014;89(1): 95-106. doi: 10.1016/j.mayocp.2013.09.016.
  23. Pichichero M.E., Casey J.R. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol. Head Neck Surg. 2007;136(3):340-47.
  24. Wargo K.A., Edwards J.D. Aminoglycoside-induced nephrotoxicity. J. Pharm. Pract. 2014;27(6):573-77. doi: 10.1177/0897190014546836.
  25. Tuon FF, Rigatto M.H., Lopes C.K., et al. Risk factors for acute kidney injury in patients treated with polymyxin B. or colistin methanesulfonate sodium. Int. J. Antimicrob. Agents. 2014;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002.
  26. Poluzzi E., Raschi E., Motola D. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System Drug Saf. 2010;33(4):303-14.
  27. Owens R.C. Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64(10):1091-124.
  28. Owens R.C. Jr., Nolin T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. CUn Infect Dis. 2006;43(12):1603-11.
  29. Goolsby T.A., Jakeman B., Gaynes R.P Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents. 2017. pii: S0924-8579(17)30332-1. doi: 10.1016/j.ijantimicag.2017.08.033.
  30. Ilgin S., Can O.D., Atli O. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-81. doi: 10.3109/15376516. 2015.1026008.
  31. Granowitz E.V, Brown R.B. Antibiotic adverse reactions and drug interactions. Crit Care Clin. 2008;24(2):421-42. Doi: 10.1016/j. ccc.2007.12.011.
  32. Mandell L. First international Moxifloxacin symposium. Berlin, 1999. Р 134-38.
  33. Клиническая фармакокинетика / Под ред. В.Г. Кукеса. М., 2009. C. 406-25. [Clinical pharmacokinetics. Ed. by V.G. Kukes. M., 2009. P. 406-25. (In Russ.)].
  34. https://www.drugs.com/
  35. Tokimatsu I., Shigemura K., Kotaki T., et al. A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. Intern Med. 2017;56(11):1315-19.
  36. Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997; 32(2):101-19.
  37. Pal D., Mitra A.K. MDR- and CYP3A4-mediateddrug-drug interactions. 2006;1(3):323-39.
  38. Varma M.V, Sateesh K., Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm. 2005;2(1):12-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies